IVST (INNOVEST Global)

$IVST (INNOVEST Global) is up 2391% YTD and added $34 million sales run rate YTD through growth model of acquisitions.

IVST (INNOVEST Global) Investment is up 2391% YTD from $0.023 on zero revenue to 0.5500 on $34 million revenue.

IVST Investment is pleased to announce that the acquisition of Authority National Supply (ANS) is closed. ANS was our sixth transaction to date, and has generated $22.8 million in sales through the first three quarters of 2018. IVST now has approximately 55 employees and $34 million in annual run-rate revenue. $IVST Investment added $34 million sales run rate YTD through growth model of acquisitions.

LOI on Pending Acquisition to add $12 Million in revenue. CEO calls it "business as usual".

IVFH Investment has ONLY 11.8M shares in the Float, unchanged for over two years. YES, NO new shares are being issued!

IVST Investment has no convertible debts, warrants, or options.

IVST Investment owns 20% of StemVax Therapeutics which is the first company in its Biotech Division.

IVST Investment has the vision and model of Berkshire-Hathaway Holding Company; we look forward to its evolution!

All information is obtained from IVST Investment issued press releases from Yahoo.com finance and www.innovestglobal.com